We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

170 hedge funds and large institutions have $1.61B invested in NxStage Medical Inc. in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 72 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

27,700% more call options, than puts

Call options by funds: $834K | Put options by funds: $3K

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

9% more funds holding

Funds holding: 156170 (+14)

0% more capital invested

Capital invested by funds: $1.6B → $1.61B (+$5.77M)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

38% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 72

Holders
170
Holders Change
+14
Holders Change %
+8.97%
% of All Funds
4.25%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.23%
New
33
Increased
45
Reduced
72
Closed
17
Calls
$834K
Puts
$3K
Net Calls
+$831K
Net Calls Change
-$12.4M
Name Holding Trade Value Shares
Change
Change in
Stake
BA
26
Broadview Advisors
Wisconsin
$13.3M +$113K +4,550 +0.9%
AGA
27
Altrinsic Global Advisors
Connecticut
$12.2M -$1.48M -60,000 -11%
Norges Bank
28
Norges Bank
Norway
$11.8M -$880K -35,600 -7%
William Blair Investment Management
29
William Blair Investment Management
Illinois
$11.6M -$170K -6,875 -2%
PC
30
Polar Capital
United Kingdom
$10.5M +$7.42M +300,000 +300%
TA
31
Tamarack Advisers
California
$9.64M -$17.5M -707,310 -66%
Two Sigma Investments
32
Two Sigma Investments
New York
$8.39M -$1.12M -45,149 -12%
N
33
Nuveen
North Carolina
$8.22M +$571K +23,084 +8%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$7.75M -$515K -20,818 -7%
Millennium Management
35
Millennium Management
New York
$7.59M -$13.8M -558,868 -66%
Prudential Financial
36
Prudential Financial
New Jersey
$7.04M -$1.44M -58,123 -18%
Charles Schwab
37
Charles Schwab
California
$6.81M -$1.73M -70,074 -21%
PVI
38
Pura Vida Investments
New York
$6.75M -$2.66M -107,500 -29%
Morgan Stanley
39
Morgan Stanley
New York
$6.59M +$2.48M +100,470 +67%
FLAM
40
First Light Asset Management
Minnesota
$6.47M -$83.4K -3,371 -1%
BIM
41
BlackRock Investment Management
Delaware
$6.24M -$17.7K -715 -0.3%
DCM
42
DAFNA Capital Management
California
$6.19M -$59.1K -2,390 -1%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$5.98M +$104K +4,200 +2%
Marshall Wace
44
Marshall Wace
United Kingdom
$5.98M +$5.64M +228,002 New
TCIM
45
TIAA CREF Investment Management
New York
$5.85M -$287K -11,587 -5%
PC
46
Pier Capital
Connecticut
$5.62M -$222K -8,988 -4%
BA
47
BlackRock Advisors
Delaware
$5.08M +$622K +25,165 +15%
DL
48
Delta Lloyd
Netherlands
$4.59M
Ameriprise
49
Ameriprise
Minnesota
$4.5M -$2.82M -113,938 -40%
RPAM
50
Rhenman & Partners Asset Management
Sweden
$4.17M +$336K +13,601 +9%

NXTM Hedge Fund Activity: Q4 2016 in Review

170 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q4 2016, worth a combined $1.61B — up 0.36% from $1.6B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new NXTM positions and 17 closed out — a net gain of 16 holders — while 45 added to existing stakes and 72 trimmed.

The largest buyer was Pennant Capital Management, adding an estimated $37.8M. The largest seller was Fidelity Investments, cutting an estimated $47.6M.

  • 170 institutional investors held NxStage Medical Inc. (NXTM) as of Q4 2016, up from 156 in Q3 2016.
  • Funds reported $1.61B of NxStage Medical Inc. stock for Q4 2016, up 0.36% quarter-over-quarter.
  • 33 funds opened new NxStage Medical Inc. positions in Q4 2016 and 17 closed out, a net change of +16 holders.
  • The largest NxStage Medical Inc. buyer in Q4 2016 was Pennant Capital Management, an estimated $37.8M added.
  • The largest NxStage Medical Inc. seller in Q4 2016 was Fidelity Investments, an estimated $47.6M sold.

Based on aggregated 13F filings for Q4 2016.